Danaher Beacon Project Launches Real-World Study on Emerging Tumor Biomarkers in Collaboration with the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences

● The Danaher Beacon project is dedicated to conducting systematic research on the expression profiles of emerging tumor biomarkers across various solid tumors.

● This study will utilize Abcam’s high-specificity antibody library (under Danaher), Leica Biosystems’ immunohistochemistry antibody reagents, and the BOND immunohistochemistry platform.

● This study will explore the biological characteristics of tumor targets, providing clinical data to support cancer subtyping and detection strategies.

(March 9, 2026, Beijing) Danaher, a global innovator in science and technology, announced the formal launch of its Danaher Beacon research collaboration with the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences. This partnership aims to build databases profiling the expression of multiple biomarkers in the Chinese population, thereby providing more valuable real-world data support for precision oncology diagnostics, companion diagnostics (CDx), and innovative drug development.

In recent years, numerous emerging tumor biomarkers, such as CLDN18.2, TROP2, and B7-H3, have demonstrated significant potential across various solid tumors, with some targeted therapies already entering pivotal clinical trials or receiving initial market approval. However, in the Chinese patient population, there is still a lack of systematic clinical data supporting the baseline expression characteristics of most emerging biomarkers, posing challenges for patient screening and enrollment in innovative drug clinical trials, as well as for the development of companion diagnostic assays.

The Danaher Beacon project focuses on this common industry challenge by conducting systematic research into the tissue expression profiles of emerging tumor biomarkers across various solid tumors, thereby constructing a more reference-worthy local data atlas.

In multi-cancer, multi-target tumor biomarker research, the stability and consistency of detection results are key to research quality. During the implementation of the study, the project will leverage high-quality archived tumor pathology samples from the Cancer Hospital of the Chinese Academy of Medical Sciences, combined with Abcam’s (a Danaher company) library of high-specificity antibodies, Leica Biosystems’ immunohistochemistry antibody reagents, and the BOND fully automated immunohistochemistry platform. By applying these mature platform capabilities and antibody resources to real-world research scenarios, the project aims to enhance the consistency and reference value of the research data.

Peng Yang, Global Vice President of Danaher and President of Danaher China Group, stated, “Danaher has long maintained a strong collaborative relationship with the Cancer Hospital of the Chinese Academy of Medical Sciences. Both parties continue to explore ways to integrate Danaher’s resources to support the advancement of oncology research and diagnostics in China. With its abundant patient resources and a vibrant environment for innovative drug development, China offers significant opportunities. Through collaboration with the cancer hospital, we aim to conduct cutting-edge research centered on patient samples to identify emerging tumor biomarkers. By fully leveraging Danaher’s capabilities in R&D and commercialization, we seek to facilitate the academic publication of research findings and ultimately translate them into clinically applicable drugs and diagnostic products, benefiting patients worldwide. Looking ahead, both parties will continue to explore emerging fields, discover more druggable targets, and jointly create greater value.”

Li Ning, Vice President of the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences, stated, “Cancer treatment is currently advancing toward precision and personalization, which requires that pathological diagnosis and tumor typing results be made available upfront to formulate optimal treatment plans for patients. We look forward to deepening our collaboration with platform-based innovative enterprises such as Danaher, closely integrating cutting-edge technologies with clinical diagnostic and therapeutic needs. Through a closed-loop model of ‘clinical questions raised, products developed by industry, and clinical validation and feedback provided,’ the mutual adaptation and synergy between both parties will effectively promote the translation and implementation of scientific research achievements.”

Ying Jianming, Director of the Department of Pathology at the Cancer Hospital of the Chinese Academy of Medical Sciences, stated, “As novel anti-tumor drugs increasingly demand precise diagnostics, the synergistic development of diagnosis and treatment has become ever more critical. This scientific research collaboration aims to proactively position itself in the fields of in vitro diagnostic reagents and companion diagnostics, leveraging high-quality medical resources to ultimately provide strong support for innovative drug development. Leica Biosystems’ pathology platform is widely applied; on this foundation, the introduction of clinically validated, high-quality antibodies will further enhance the platform’s capabilities, accelerate the translation of scientific achievements, and expand from the Chinese market to the global stage.”

Fang Chao, Chief Scientific Officer of Danaher China, stated, “As a core tool in precision oncology, companion diagnostic technology plays a significant role in optimizing new drug development and clinical treatment. Through in-depth collaboration with the Cancer Hospital of the Chinese Academy of Medical Sciences, we aim to establish a more robust local data foundation to support the development and application of companion diagnostic reagents, thereby providing more effective personalized treatment solutions for cancer patients.”

The Danaher Beacon Program is a cutting-edge scientific research initiative launched globally by Danaher in collaboration with top academic institutions and research institutes. It aims to conduct advanced scientific research and develop innovative technologies and applications that improve human health. The program focuses on areas including genomic medicines, precision diagnostics, next-generation biopharmaceutical manufacturing, human systems, and data science.

Danaher is an innovator in the fields of life sciences and medical diagnostics, dedicated to accelerating scientific and technological advancements to improve human health. We collaborate closely with our customers to address the many critical health challenges facing patients worldwide. Danaher’s advanced science and technology, combined with its proven track record of innovation, not only enable faster and more accurate medical diagnostics but also effectively reduce time and costs, thereby facilitating the sustainable discovery, development, and delivery of life-changing therapies. Guided by a commitment to scientific excellence, innovation, and continuous improvement, Danaher’s approximately 63,000 associates worldwide help enhance the quality of life for billions of people today while laying the foundation for a healthier, more sustainable future. For more information, please visitwww.danaher.com.cn。